drugset / Trial / NCT05216510
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the presence and magnitude of DTH reactions.
Timeline
- Start
- 2022-01-07
- Primary completion
- 2022-09-17
- Completion
- 2022-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TNX-2110 | Unknown | 0.1 ml | Other |
| Subject | TNX-2120 | Unknown | 0.1 ml | Other |
| Subject | TNX-2130 | Unknown | 0.1 ml | Other |
| Background | Candin | Other / unclassified | 0.1 ml | Other |